Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for thrombocytopenia in low- or intermediate-1-risk myelodysplastic syndromes
2010-022890-33Phase 2Active
- Sponsor
- Qol-one
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Eltrombopag with Placebo (2 arms). Primary endpoints: Platelet response rate and Safety and tolerability. Started Nov 2010; status: active.
02
Drugs
eltrombopag
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2010-022890-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022890-33.